ATE55151T1 - Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen. - Google Patents

Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen.

Info

Publication number
ATE55151T1
ATE55151T1 AT84300091T AT84300091T ATE55151T1 AT E55151 T1 ATE55151 T1 AT E55151T1 AT 84300091 T AT84300091 T AT 84300091T AT 84300091 T AT84300091 T AT 84300091T AT E55151 T1 ATE55151 T1 AT E55151T1
Authority
AT
Austria
Prior art keywords
yeast
synthesis
expression systems
foreign proteins
containing vectors
Prior art date
Application number
AT84300091T
Other languages
English (en)
Inventor
Rae Lyn Burke
Olson Patricia Tekamp
Steven Rosenberg
Pablo D T Valenzuela
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23860419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE55151(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE55151T1 publication Critical patent/ATE55151T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Toys (AREA)
AT84300091T 1983-02-22 1984-01-06 Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen. ATE55151T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46858983A 1983-02-22 1983-02-22
EP84300091A EP0120551B1 (de) 1983-02-22 1984-01-06 Expressionssysteme für Hefe mit einen GAPDH Promotor enthaltenden Vektoren und Synthese von Fremdproteinen

Publications (1)

Publication Number Publication Date
ATE55151T1 true ATE55151T1 (de) 1990-08-15

Family

ID=23860419

Family Applications (3)

Application Number Title Priority Date Filing Date
AT89106868T ATE93894T1 (de) 1983-02-22 1984-01-06 Expressionssysteme fuer hefe mit pyk-promotoren enthaltenden vektoren und synthese von fremdproteinen.
AT91114001T ATE138975T1 (de) 1983-02-22 1984-01-06 Expressionssysteme für hefe mit vektoren, die einen gapdh-promotor enthalten und oberflächenantigensynthese von hepatitis b
AT84300091T ATE55151T1 (de) 1983-02-22 1984-01-06 Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT89106868T ATE93894T1 (de) 1983-02-22 1984-01-06 Expressionssysteme fuer hefe mit pyk-promotoren enthaltenden vektoren und synthese von fremdproteinen.
AT91114001T ATE138975T1 (de) 1983-02-22 1984-01-06 Expressionssysteme für hefe mit vektoren, die einen gapdh-promotor enthalten und oberflächenantigensynthese von hepatitis b

Country Status (7)

Country Link
EP (4) EP0732403A1 (de)
JP (2) JPS59210888A (de)
AT (3) ATE93894T1 (de)
CA (2) CA1341302C (de)
DE (3) DE3486431T3 (de)
DK (1) DK173604B1 (de)
SG (1) SG48422A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
JPS5931799A (ja) * 1982-08-16 1984-02-20 Science & Tech Agency Ｂ型肝炎ウイルス遺伝子を組込んだ組換えプラスミド
JPS5936699A (ja) * 1982-08-20 1984-02-28 Chemo Sero Therapeut Res Inst シヤトルベクタ−
US5422267A (en) * 1984-05-22 1995-06-06 Robert R. Yocum Industrial yeast comprising an integrated glucoamylase gene
EP0173997A1 (de) * 1984-09-06 1986-03-12 Chiron Corporation Katzenleukämievirusproteinimpfstoffe und ihre Herstellung
DE3587307T2 (de) * 1984-12-06 1993-09-02 Fina Research Transformierte hefen die lysozym produzieren, fuer diese transformation zu verwendende plasmide und deren verwendung.
DE3677851D1 (de) * 1985-08-05 1991-04-11 Merck & Co Inc Verfahren zur steigerung der produktion von rekombinantem protein in hefearten der gattung saccharomyces.
JPH0655155B2 (ja) * 1985-10-03 1994-07-27 株式会社ミドリ十字 蛋白質の製造方法
ES2028779T3 (es) * 1985-10-03 1992-07-16 Green Cross Corporation Promotor de levadura y procedimiento para preparar proteina heterologa.
DK162900C (da) * 1985-10-24 1992-05-11 Danisco Fremgangsmaade til ekspression af gener i gaer samt dna-fragment, rekombineret dna-segment og plasmider, hvor disse indgaar til brug ved udoevelse af fremgangsmaaden
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
JPS62236496A (ja) * 1986-04-07 1987-10-16 Green Cross Corp:The ＨＢｓＡｇの製造方法
US4839283A (en) * 1986-12-30 1989-06-13 Zymogenetics, Inc. Method of expressing alpha-1-antitrypsin in yeast
ATE207535T1 (de) * 1987-06-22 2001-11-15 Medeva Holdings Bv Hepatitis-b-oberflächenantigen enthaltendes peptid
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
AU644619B2 (en) 1989-12-21 1993-12-16 Advanced Technologies (Cambridge) Limited Modification of plant metabolism
FI103206B (fi) * 1990-01-29 1999-05-14 Novartis Ag Uusi ilmentämisjärjestelmä sieniä varten
US6194140B1 (en) 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
DK0574402T3 (da) 1990-11-26 1998-05-18 Chiron Corp Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
CA2162557C (en) 1993-05-12 2004-09-28 Amy J. Weiner Conserved motif of hepatitis c virus e2/ns1 region
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
JPH08173170A (ja) * 1994-05-25 1996-07-09 Kirin Brewery Co Ltd キャンディダ・ユティリス酵母の形質転換系、およびそれによる異種遺伝子の発現
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
ES2229288T3 (es) 1995-12-22 2005-04-16 Dsm Ip Assets B.V. Metodos mejorados para transformar cepas de phaffia, cepas de phaffia transformadas asi obtenidas y dna recombinante en dichos metodos.
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
US6087128A (en) 1998-02-12 2000-07-11 Ndsu Research Foundation DNA encoding an avian E. coli iss
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
JP5102414B2 (ja) 1998-05-01 2012-12-19 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 髄膜炎菌抗原および組成物
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
CN100392082C (zh) 1999-04-30 2008-06-04 启龙股份公司 保守的奈瑟球菌抗原
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
US6709863B2 (en) 1999-12-08 2004-03-23 Iowa State University Research Foundation Nucleic acid molecules encoding multiple start codons and histidine tags
CN1416352B (zh) 2000-01-17 2011-05-25 启龙股份公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
EP1328543B1 (de) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nukleinsäuren und proteine von gruppen a und b-streptokokken
WO2002059297A2 (en) 2001-01-25 2002-08-01 Evolva Biotech A/S A library of a collection of cells
US8008459B2 (en) 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
ES2386386T3 (es) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
WO2003099854A2 (en) 2002-05-24 2003-12-04 Nps Allelix Corp. Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
SI1704234T1 (sl) 2003-11-21 2012-08-31 Nps Pharma Inc Proizvodnja glukagonu podobnih peptidov 2 in analogov
DE10356218A1 (de) * 2003-12-03 2005-06-30 Bayer Cropscience Ag Verfahren zum Identifizieren von fungizid wirksamen Verbindungen basierend auf Pyruvatkinasen aus Pilzen
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
JP2008525473A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
CA2590429C (en) 2004-12-22 2014-10-07 Ambrx, Inc. Compositions of aminoacyl-trna synthetase and uses thereof
SG158148A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2006113528A2 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
CN102703446B (zh) 2005-08-18 2014-05-28 Ambrx公司 tRNA组合物和其用途
EP2308505A3 (de) 2005-09-01 2011-11-30 Novartis Vaccines and Diagnostics GmbH Mehrfachimpfstoff einschließlich Meningokokken der Serogruppe C
PT2339014E (pt) 2005-11-16 2015-10-13 Ambrx Inc Métodos e composições compreendendo aminoácidos não-naturais
CA2882445A1 (en) 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US20110206692A1 (en) 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
WO2008030613A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
KR20090060294A (ko) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
WO2008139591A1 (ja) * 2007-05-11 2008-11-20 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 組換えアプロチニンの生産方法
JP5547083B2 (ja) 2007-11-20 2014-07-09 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
UA118536C2 (uk) 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
KR101647164B1 (ko) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
NZ607477A (en) 2008-09-26 2014-09-26 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
CN107056929A (zh) 2009-12-21 2017-08-18 Ambrx 公司 经过修饰的猪促生长素多肽和其用途
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
EP2571991A1 (de) 2010-05-20 2013-03-27 Evolva SA Verfahren zur herstellung von isoprenoidverbindungen in hefe
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MX346786B (es) 2010-08-17 2017-03-31 Ambrx Inc Polipeptidos de relaxina modificados y sus usos.
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
PL3412302T3 (pl) 2014-10-24 2021-11-02 Bristol-Myers Squibb Company Zmodyfikowane polipeptydy fgf-21 i ich zastosowania
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
GR76274B (de) * 1981-08-04 1984-08-04 Univ California
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
JP2608540B2 (ja) * 1982-05-19 1997-05-07 ギスト ブロカデス ナ−ムロ−ゼ フエンノ−トチヤツプ クルイベロミセス種のためのクローニング系
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
JPH0716432B2 (ja) * 1982-10-20 1995-03-01 サントリー株式会社 酵母の高発現ベクタープラスミドを用いたペプチドの生産方法

Also Published As

Publication number Publication date
DE3486431T2 (de) 1996-10-10
EP0120551A2 (de) 1984-10-03
SG48422A1 (en) 1998-04-17
EP0460716A1 (de) 1991-12-11
DE3486206D1 (de) 1993-10-07
JPH05268984A (ja) 1993-10-19
CA1341116C (en) 2000-10-17
ATE93894T1 (de) 1993-09-15
DE3486206T2 (de) 1994-02-03
EP0120551B1 (de) 1990-08-01
ATE138975T1 (de) 1996-06-15
EP0329203B1 (de) 1993-09-01
EP0329203A1 (de) 1989-08-23
JPS59210888A (ja) 1984-11-29
JPH0724594B2 (ja) 1995-03-22
DK173604B1 (da) 2001-04-23
EP0120551A3 (en) 1986-05-14
EP0460716B2 (de) 1999-12-15
DE3482844D1 (de) 1990-09-06
DK577783A (da) 1984-08-23
EP0460716B1 (de) 1996-06-05
DK577783D0 (da) 1983-12-15
CA1341302C (en) 2001-10-09
DE3486431T3 (de) 2000-05-04
DE3486431D1 (de) 1996-07-11
JPH0515431B2 (de) 1993-03-01
EP0732403A1 (de) 1996-09-18

Similar Documents

Publication Publication Date Title
ATE55151T1 (de) Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen.
EP1245678A3 (de) Rekombinante Proteine von mit Lymphadenopathiesyndrom und/oder erworbenem Immunschwächesyndrom assoziierten Viren
AU6733487A (en) Mammalian interleukin-4
ES8603957A1 (es) Procedimiento para obtener una proteina heterologa para levadura
ES2123006T3 (es) Levaduras recombinantes altamente estables para la produccion de proteinas recombinantes.
ES8504938A1 (es) Un metodo de producir una proteina interferon inmune humano
NO854460L (no) Syntetisk hepatitis-b-vaksine inbefattende baade t-celle og b-celledeterminanter.
DK27885A (da) Fremstilling af peptider
ES8505253A1 (es) Un procedimiento para preparar un organismo unicelular que tiene una secuencia de adn que codifica un plipeptid0 que tiene un determinante inmunorreactivo u antigeno de una glicoproteina de virus de herpes simplex.
AU7378087A (en) Interleukin-2 induced antineoplastic peptide
DK107493A (da) Vektor for udtrykkelse i gaer, bestaaende af et fremmed dna-segment og en fremgangsmaade til syntese af fremmede proteiner ved hjaelp af en saadan vektor
ATE93893T1 (de) Expressionssysteme zur ueberproduktion gewuenschter proteine.
FI934079A (fi) Menetelmä fuusioproteiinin valmistamiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time